Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
For practices operating at scale, the metabolic health EMR workflow includes templated diabetes review sections that prompt clinicians to document all active antidiabetic agents, confirm therapy duration, and tag insulin use as ongoing rather than situational
SS-31 targets mitochondrial function
June 27 : The FDA approved UCBs Rystiggo (rozanolixizumab), a subcutaneously administered humanized IgG4 monoclonal antibody, to treat generalized myasthenia gravis, a rare muscle-wasting autoimmune disease
Handler P, Brabander D
doi:10.1172/JCI112855
US$ 24.59
US$ 20.68
US$ 26.06
US$ 28.01
US$ 29.64
US$ 22.47
